Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Shares Issued (2016 - 2025)

Historic Shares Issued for Perspective Therapeutics (CATX) over the last 14 years, with Q3 2025 value amounting to $226000.0.

  • Perspective Therapeutics' Shares Issued fell 6479.75% to $226000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $275.3 million, marking a year-over-year increase of 2114089.51%. This contributed to the annual value of $275.8 million for FY2024, which is 4968465.7% up from last year.
  • Latest data reveals that Perspective Therapeutics reported Shares Issued of $226000.0 as of Q3 2025, which was down 6479.75% from $145000.0 recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Shares Issued high stood at $274.9 million for Q4 2024, and its period low was $22000.0 during Q3 2023.
  • Its 5-year average for Shares Issued is $21.9 million, with a median of $145000.0 in 2025.
  • The largest annual percentage gain for Perspective Therapeutics' Shares Issued in the last 5 years was 6862775.0% (2024), contrasted with its biggest fall of 7593.98% (2024).
  • Quarter analysis of 5 years shows Perspective Therapeutics' Shares Issued stood at $28000.0 in 2021, then grew by 7.14% to $30000.0 in 2022, then soared by 1233.33% to $400000.0 in 2023, then skyrocketed by 68627.75% to $274.9 million in 2024, then tumbled by 99.92% to $226000.0 in 2025.
  • Its last three reported values are $226000.0 in Q3 2025, $145000.0 for Q2 2025, and $274.9 million during Q4 2024.